Zacks.com on MSN2d
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.
Morgan Stanley Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
American Association of Individual Investors3d
Which Is a Better Investment, Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG Stock?
Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Nasdaq8d
CRSP March 7th Options Begin Trading
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
pharmaphorum4d
Bayer and CRISPR Therapeutics launch gene drug discovery venture
The JV will be led by Dr Axel Bouchon, head of the BLSC, on an interim basis as CEO, while Dr Rodger Novak, CEO and co-founder of CRISPR Therapeutics, will serve as the interim chairman of the ...
pharmaphorum11d
Vertex and CRISPR Therapeutics to collaborate on genetic disease research
Dr Emmanuelle Charpentier is the founder of CRISPR Therapeutics, and one of the scientists credited with its discovery. However Charpentier is competing with rivals and former colleagues who have ...
STAT8d
Tris Pharma, looking to compete with Vertex, reports acute pain trial success
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...